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ABSTRACT One limit to succesdl receptor-mediated
gene delivery is the exit of the endocytosed material from the
endosome. We demonstrate here the delivery of marker genes
to tissue culture cells using a modification of the receptor-
mediated gene delivery technique that exploits the endoso-
molytic activity ofdefective adenovirus particles. In particular,
>90% of the transfected-cell population is found to express a
(-galactosidase gene, and, most importantly, this hig level of
expression can be obtained with psoralen-inactivated virus
particles. Furthermore, because the delivered gene is not
carried within the genome of the adenovirus particle, the size
constraints are relieved, and we can, therefore, show the
delivery of a 48-kilobase cosmid DNA molecule.
We are developing methods of introducing DNA into mam-
malian cells with the goal of generating a safe and reliable
method that introduces both small and large DNA into a high
percentage ofthe target cells. Our strategy has been to exploit
the receptor-mediated endocytosis route to deliver DNA.
This approach uses various polycation-ligand chemical con-
jugates, such as transferrin-polylysine (1-5), which serve to
condense the DNA to be transferred into compact, ligand-
coated toroids, comparable in size to a typical DNA virus (6).
These ligand-coated DNA particles can then bind to recep-
tors on the surface of target cells, and upon endocytosis, the
DNA finds its way into the nucleus.
We have demonstrated both transient and stable gene
delivery into a variety of cell types. In certain cell lines, such
as K-562 cells, we can show transient gene expression in
>90% of the target cells (5). Stable expression of introduced
genes can also be demonstrated, with up to 0.5-1% of the
initial transfected-cell population recoverable as stable ex-
pressing clones (unpublished results).
We suspected that one of the major limits to gene delivery
by endocytosis in many cell types may be the exit of the
endocytosed material from the endosome. However, many
viruses are known to enter cells via a similar receptor-
mediated endocytosis route and possess molecular skills to
mediate disruption of the endosomes to enter the cytoplasm
of host cells. We have previously found that this endoso-
molytic activity ofa virus can function in trans to facilitate the
coentry of receptor-bound DNA particles (7). Plasmid DNA
containing a marker gene is complexed and condensed into a
compact parcel with polylysine covalently linked to a cell-
binding ligand, such as transferrin. When these ligand-coated
DNA donuts are supplied to the appropriate cells in the
presence of a replication-defective adenovirus, both the
DNA complex and the virus are endocytosed, and the
low-pH-triggered adenoviral endosome disruption allows ef-
ficient cellular entry of the DNA (Fig. 1). This maneuver
enhances delivered gene expression 100- to 1000-fold in a
variety of cell types (7, 8).
We present evidence here that when the target cell displays
receptors for both the DNA-bound ligand (transferrin) and
adenovirus, a very high percentage (>90%) of the target cells
take up and express the marker gene. This trans application of
virus solves many of the safety and practical problems asso-
ciated with using recombinant viruses to deliver genes. In our
system, the virus is functioning merely as an endosomolytic
agent, and because virus gene expression is not required, we
can use a transcription- and replication-defective virus. Most
importantly, because the endosomolytic activity ofthe virus is
probably a function ofthe virus protein capsid, we find thatwe
can treat the virus with various agents that damage the nucleic
acid of the virus while sparing the protein component, such as
short-wave UV radiation or the DNA intercalator psoralen
plus long-wave UV, and the DNA-delivery activity ofthe virus
is largely retained. These inactivation protocols further block
virus gene expression and replication. Because the virus
particle is functioning in trans and the DNA to be delivered is
not incorporated within the virus capsid, this system allows
great size and sequence variety in the DNA to be delivered; in
contrast to the 6- to 8-kilobase (kb) size limit of the standard
recombinant adenovirus vectors (9), we routinely deliver
15-kb plasmids, and we demonstrate here the functional
delivery of a 48-kb luciferase-encoding cosmid. Furthermore,
the fact that the cargo DNA need not participate in the
replication steps of the virus (as is required with the se-
quences carried by recombinant virus vectors) relieves a
further constraint on the length and types ofDNA sequences
that a given virus can transport.
This use of a defective-virus particle in trans represents
another class of gene-delivery techniques. It combines the
entry efficiency of a virus with the flexibility and safety of a
number of nonviral methods. We believe that this approach
provides another way of thinking about DNA delivery and
facilitates a variety of possibilities for molecular biology and
gene-therapy applications.
METHODS
General Methods. Human and mouse transferrin-polyly-
sine (hTfpL, mTfpL), asialofetuin-polylysine (AfpL), and
galactose-polylysine (gal)4pL, were prepared and character-
ized as described (1, 4, 5; E.W., unpublished results). All
DNA preparations (plasmid or cosmid) were subjected to two
Abbreviations: FCS, fetal calf serum; CosLuc, luciferase cosmid;
AfpL, asialofetuin-polylysine; hTfpL and mTfpL, human and mouse
transferrin-polylysine, respectively; (gal)4pL, galactose-polylysine
conjugate; DMEM, Dulbecco's modified Eagle's medium; DMEM +
10%oFCS, DMEM/2 mM glutamine/streptomycin at 10 ,uglml/
penicillin at 100 units/ml/10%o FCS.
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FIG. 1. Summary of adenovirus-enhanced receptor-mediated
gene delivery. DNA condensed with transferrin-polylysine conju-
gate is supplied to cells in the presence of adenovirus particles. Upon
coendocytosis, a low-pH-triggered change of the virus capsid is
thought to generate endosome disruption, allowing release of coen-
docytosed transferrin-polylysine/DNA.
rounds of isopycnic banding on CsCl, as described (5). HeLa,
mouse hepatocyte BNL CL.2, and human neuroblastoma
GI-ME-N cells (10) were grown in Dulbecco's modified
Eagle's medium (DMEM)/2 mM glutamine/streptomycin at
10 ug/ml/penicillin at 100 units/ml/10% fetal calf serum
(FCS) (DMEM+10%FCS).
Preparation of Adenovirus d1312. Adenovirus d1312, a rep-
lication-defective strain of human adenovirus 5 lacking func-
tional Ela sequences (11), was propagated on the comple-
menting cell line 293 (12) as described (7). Virus was isolated
by two rounds of CsCl density-gradient purification, diluted
with an equal volume of glycerol, and stored at -70TC.
Viral titers were determined by end-point dilution, cyto-
pathic effect (CPE) assay on 293 cells (13), by UV-
absorbance measurement of extracted viral DNA [using the
relationship 1 absorbance unit at 260 nm (A260) equals 1012
viral particles per ml] (14) and by protein content (using the
relationship 1 mg of viral protein = 3.4-3.5 x 1012 virus
particles) (15).
Preparation of Luciferase Cosmid (CosLuc). A 3.0-kb Sal I
fragment, containing a single Photinus pyralis luciferase-
coding sequence under the control of the Rous sarcoma virus
promoter, was isolated from the plasmid p22ORSVLuca and
ligated into the unique Sal I site of the cosmid clone C1-7aA1
(provided by A. Weith, Vienna) to form concatemers. Cl-
7aAl comprises a 37-kb human genomic DNA Sau3A frag-
ment (partial digest), encoding no apparent genes, cloned into
the BamHI site of the cosmid vector pWE15 (Stratagene). The
ligation reaction was then packaged in vitro, and an aliquot of
the resulting phage particles were infected into Escherichia
coli NM554 and plated on LB ampicillin plates. The recom-
binants were screened by colony hybridization using the
3.0-kb Sal I fragment (32p labeled by random priming) as a
hybridization probe, and a number of positives were analyzed
by restriction mapping. A cosmid construct (CosLuc) contain-
ing a single copy of the Sal I insert was grown and purified on
a CsCl gradient (total size = 48 kb).
The small control cosmid pWELuc (12 kb) was prepared by
digesting CosLuc with Not I, religating, transforming bacte-
ria, and isolating a clone containing the appropriate plasmid.
This procedure resulted in a 12-kb DNA molecule lacking the
human DNA insert and part of the polylinker of CosLuc 1.
The plasmid clone pSPNeoLuc (8 kb) was obtained by
ligating the 3.0-kb Sal I fragment from p22ORSVLuca de-
scribed above into the Sal I site ofpSPNeo, a vector prepared
by ligating a Xba I-Asp-718/Klenow blunt-ended fragment
containing the polylinker of Bluescript M13+ into the Xba I
andBamHI/S1 nuclease blunt-ended sites ofpSSTneoA. The
plasmid pSSTneoA is the large Sst I fragment from
pUCplocus (16).
Transfection Protocols. In general, 6 pug ofDNA was diluted
in 330 1.l of HBS (20 mM Hepes/150mM NaCl, pH 7.4) and
a sample of hTfpL, mTfpL, AfpL, or (gal)4pL (equivalent to
4 jig of polylysine) was diluted with 170 pl of HBS. The two
solutions were mixed and allowed to incubate at room
temperature for 30 min. One ml ofDMEM/2%FCS was then
added to the mixture followed by a sample of the adenovirus
(quantities are specified in the figure legends). The medium
was removed from a 6-cm dish of cells (grown to :'-80%o
confluence) and replaced with the DNA/hTfpL/adenovirus
mixture. After a 1-hr incubation at 37°C, 4 ml of DMEM+
10%oFCS was added to the dish. Transfections using chloro-
quine contained 100 ,uM chloroquine during a 4-hr exposure to
the DNA/conjugates, after which the cells were washed into
fresh 10%o FCS-containing medium. After a 24-hr incubation at
37°C, the cells were harvested for luciferase assay (5).
Psoralen Inactivation. Samples of purified virus were
adjusted to 0.33 ,ug/,l of 8-methoxypsoralen solution (stock
concentration 33 ,g/,ul 8-methoxypsoralen dissolved in di-
methyl sulfoxide), and exposed to a 365-nm UV light source
(UVP model TL-33) on ice, at 4 cm from the lamp filter;
exposure to the UV light was for 15-30 min, as indicated in
the figure legends. The virus samples were then passed over
a Sephadex G-25 column (Pharmacia, PD-10) equilibrated
with HBS/40%o (vol/vol) glycerol.
RESULTS
What Percentage of Transfected Cells Express the Gene? We
have previously demonstrated that transient DNA delivery
into HeLa cells is augmented by a factor of 1000 or more
when cells are simultaneously exposed to transferrin-
polylysine/DNA complexes and replication-defective aden-
ovirus particles (7). Our hypothesis has been that the trans-
ferrin-polylysine-complexed DNA is efficiently endocytosed
into a large percentage of the transfected cell population (8)
but that the exit from the endosome into the cytoplasm occurs
in only a limited number of cells. This endosomal exit is
promoted either by agents that induce endosomal or lyso-
somal swelling, such as chloroquine (2, 3), or by the endo-
somal disruption induced by adenovirus (17-21). We wanted
to know what percentage of cells transiently express genes
introduced by adenovirus/transferrinfection. We exposed
HeLa cells to hTfpL/DNA complexes containing a plasmid
construct of B-galactosidase under control of the cytomega-
lovirus immediate-early promoter/enhancer (22) and then
added either 100 ,uM chloroquine or defective-adenovirus
particles. After staining of transfected cells 48 hr later with
the chromogenic substrate 5-bromo-4-chloro-3-indolyl /3-D-
galactoside (X-Gal) (23), we find <0.1% of a transfected
HeLa cell population stains positive (Fig. 2A), and there is
only a slight improvement when transfection is done with 100
,uM chloroquine (Fig. 2B). However, >90% of the cells stain
positive when the transferrinfection is done with adenovirus
(Fig. 2C). Furthermore, high-level transient expression can
be obtained with a number of other cell types, including the
mouse hepatocyte line BNL CL.2 with (gal)4pL (Fig. 2D) or
mTF pL (Fig. 2E) and a neuroblastoma line GI-ME-N (data
not shown). Psoralen-inactivated adenovirus (see below)
provides DNA-delivery augmentation similar to that ob-
tained with nontreated adenovirus d1312 (Fig. 2F). Note,
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FIG. 2. /3-Galactosidase staining patterns of various transfected-
cell populations. (A) HeLa cells transfected with hTfpL. (B) HeLa
cells transfected with hTfpL in the presence of 100 ,utM chloroquine.
(C) HeLa cells transfected with hTfpL in the presence of adenovirus
d1312. (D) BNL CL.2 cells transfected with (gal)4pL+adenovirus
d1312. (E) BNL CL.2 cells transfected with mTfpL+adenovirus
d1312. (F) HeLa cells transfected with hTfpL+psoralen-inactivated
adenovirus d1312. In all samples the virus particle-to-cell ratio was
5,000-10,000:1 .
however, that a certain cell toxicity (the presence of small,
dark, rounded cells) is associated with high-level DNA de-
livery in the HeLa cells (Fig. 2C), and this toxicity can be
partially relieved by psoralen treatment of the virus (Fig. 2F).
Augmentation of Delivery Involving Other Receptor-Ligand
Pairs. Does the adenovirus augmentation occur with other
receptor/ligand systems? Successful receptor-mediated gene
delivery to hepatocytes has been obtained using asialogly-
coprotein-polylysine conjugates that bind to the liver-
specific asialoglycoprotein receptor (24, 25). We have devel-
oped a completely synthetic, galactose-containing, polyly-
sine conjugate that presents as the receptor-recognition
signal a cluster of four lactose moieties attached to a syn-
thetic, branched linker peptide (E.W., unpublished results),
which serves to target DNA delivery to hepatocytes. We
tested the adenovirus-delivery enhancement of DNA deliv-
ered with this synthetic ligand [(gal)4pL] as well as a natural
asialoglycoprotein receptor ligand (AfpL) and mTfpL.
These three different ligand polylysine conjugates were
tested for DNA delivery into the mouse hepatocyte line BNL
CL.2 (Fig. 3). Delivery was tested in the absence of an
endosomolytic agent (bars 1, 4, 7), in the presence of 100 puM
chloroquine (bars 2, 5, 8), and in the presence of adenovirus
d1312 particles (bars 3, 6, 9). We find very little delivery with
any conjugate in the absence of chloroquine, modest delivery
in the presence of chloroquine, and a very robust enhance-
ment with all three conjugates in the presence of adenovirus.
Hence, the DNA-delivery enhancement observed with
DNA delivered with transferrin-polylysine conjugates is not
unique for the transferrin receptor. Adenovirus can also
function to augment delivery into hepatocytes by using both
synthetic [(gal)4pL] and natural (AfpL) asialoglycoprotein-
receptor ligands. In this hepatocyte line, the liver-specific
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FIG. 3. BNL CL.2 mouse hepatocytes transfected with mTfpL,
AfpL, or (gal)4pL alone, with 100 ,uM chloroquine or with 10I.1 of
adenovirus d1312 containing 5 x 1011 particles per ml.
asialoglycoprotein conjugates function with efficiencies com-
parable to the transferrin conjugates.
Physical and Chemical Inactivation of Adenovirus Without
Disrupting DNA-Delivery Activity. Previous studies have
demonstrated that heat-inactivated (450C) adenovirus d1312
no longer supports DNA delivery (7), consistent with the idea
that the endosome-disruption activity is a property of the
protein capsid of the virus and, thus, denaturing this protein
component interferes with the delivery. The nucleic acid of
the virus apparently plays no role in the entry event. Al-
though we are using a deletion mutant ofadenovirus reported
to be replication defective, at some of the high-input doses of
virus this block has a certain leakiness with both early gene
expression and viral replication occurring (ref. 11 and our
own observations). This leakiness may be accompanied by
toxicity, which interferes with the long-term viability of the
transfected cells. Therefore, we sought additional physical
and chemical methods of inactivating the viral nucleic acid
without damaging the endosome-disruption activity of the
protein capsid. We initially attempted short-wave UV irra-
diation, hoping to introduce lesions in the DNA of the virus
while sparing the protein components. UV-inactivated ade-
novirus has been reported to function in augmenting epider-
mal growth factor-toxin entry into target cells (18).
Preparations of adenovirus were irradiated with 260-nm
UV light for various times and then tested for their ability to
support DNA delivery (as measured by luciferase-DNA
delivery into HeLa cells) and also tested for their ability to
replicate on 293 cells. We find that a 300-sec exposure
generates a 4-logarithm drop in viral titer that is accompanied
by a 1-logarithm drop in the ability of the virus preparation to
augment DNA delivery (Fig. 4A). Thus, it is possible to
inactivate viral-replication functions without seriously im-
pairing the endosome disruption activity.
We sought a greater decrement in viral titer with less
damage to the protein component. The psoralens are a class
of small, hydrophobic molecules that can readily diffuse into
intact virus particles and intercalate into the nucleic acid.
Upon irradiation at 365 nm, the compounds form a covalently
crosslinked structure that interferes with both transcription
and replication reactions (26). Psoralen treatment followed
by 365-nm UV irradiation has proven to be an effective means
of inactivating a variety ofboth enveloped and nonenveloped
virus contaminations in various blood protein preparations
while generating only a modest inactivation of the active
protein component in the preparation (27-29). The DNA in
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FIG. 4. Virus inactivation with either short-wave UV irradiation
(A) or with long-wave UV plus 8-methoxypsoralen treatment (B). In
A and B, viral preparations were tested either for their activity in
augmenting pCLuc-hTfpL conjugate delivery into HeLa cells by
using a virus-to-cell ratio of 1000:1 (as evidenced by the resulting light
units of luciferase activity, right ordinates) or for the ability to
replicate in 293 cells (viral titer, left ordinates).
intact adenovirus virions has been shown to be accessible to
and capable of being crosslinked with psoralen (30).
We treated purified adenoviral samples with 8-methoxy-
psoralen followed by 10 or 30 min of 365-nm UV light. The
unbound 8-methoxypsoralen was then removed by gel filtra-
tion, and the adenovirus preparations were assayed for viral
titer (by cytopathic effect assay on 293 cells) and for their
ability to support luciferase-DNA delivery. We find 8-meth-
oxypsoralen exposure coupled with 10 min of 365-nm UV
generates a 4-logarithm drop in virus titer; when 8-methoxy-
psoralen exposure is coupled with 30-min UV exposure, a
>5-logarithm drop is generated, and this is accompanied by
only a 2- to 3-fold drop in luciferase-DNA-delivery activity
(Fig. 4B).
Delivery of 48-kb DNA. Although the use of recombinant
viruses to deliver genes to eukaryotic cells has become
routine in many laboratories, these vectors are generally
limited in the size and type of DNA sequences that can be
carried within the viral genome. The commonly used Molo-
ney retroviral constructs have a size limit in the range of 5 kb
(31, 32). Recombinant adenovirus constructs allow delivery
of 8 kb of additional sequences (9, 33-35). The parvovirus
constructs have a strict 5-kb capacity (36-38).
The size of polycation-condensed DNA particles shows a
curious feature, in that the final size of the particle is
relatively insensitive to the size of the DNA molecule used
(39-41). Therefore, the delivery of large DNA molecules into
cells may be possible with the adenovirus augmentation ifwe
perform the condensation correctly. Certainly we have no
clear indication of the size of the lesions generated within the
endosome by the adenovirus particle, if, in fact, these are
discrete holes and not a general fragmentation of the vesicle.
The major limit may be the size of a particle that can be
engulfed in a single endocytic invagination; EM studies have
shown coated pits to have diameters of 100-200 nm (42, 43).
With this in mind, we have tested the delivery efficiency of
a Rous sarcoma virus-luciferase gene present on either an
8-kb circular DNA plasmid or on a 48-kb circular DNA
cosmid. We find very little DNA delivery using the transfer-
rin-polylysine system in the absence ofadenovirus and in the
presence of chloroquine with HeLa cells (Fig. 5A, bar 2),
whereas the small plasmid is delivered successfully into these
cells (Fig. 5A, bar 1). However, we find that with HeLa cells
in the presence of the adenovirus, the resulting luciferase
activity (as an indication of productive delivery ofDNA into
the target cells) is virtually the same for the 8-kb and the 48-kb
DNA molecules testingDNA quantities from 6 to 0.5 ,ug (Fig.
5A, rows 3-12). With a neuroblastoma cell line GI-ME-M,
these difficult-to-transfect cells show very little activity with
either a small 12-kb luciferase plasmid or the 48-kb luciferase
cosmid when the DNA complexes are delivered alone (Fig.
5B, bars 1 and 2) or in the presence of chloroquine (bars 3 and
4). Again we find that in the presence of adenovirus, high
levels of luciferase activity are obtained (Fig. SB, bars 5 and
6) with a 6-fold difference in activity between the small and
the large DNA molecules. Note that these results are ex-
pressed in terms of mass ofDNA delivered; the cosmid has
one luciferase gene per 48 kb, whereas the plasmid has one
luciferase gene per 12 kb; therefore, the 6-fold difference is
equivalent to a 1.5-fold difference on a molar basis.
DISCUSSION
We have previously demonstrated that the endosome-
permeabilization activity of defective-adenovirus particles
can be exploited to enhance receptor-mediated gene delivery
(7, 8). We have explored here some of the additional features
of the adenovirus augmentation. We find that transient trans-
fection efficiencies approaching 100%o can be obtained when
a chromogenic marker gene is introduced with this technique.
We have explored the variety of receptors that can be
cointernalized with the adenovirus receptor and are, thus,
amenable to the augmentation effect. We also find that DNA
delivery with conjugates that bind the asialoglycoprotein re-
ceptor (Fig. 3) and conjugates that bind CD4 can also be
enhanced with adenovirus treatment (M.C., unpublished re-
sults). Although this is only a test sample of three different
receptors, this work suggests that internalized receptors reach
a common endosomal pool. The limit will now be the expres-
sion of the adenovirus receptor of the target cells. However,
additional strategies linking the adenovirus particle to the
polylysine-ligand/condensed DNA have been developed (44,
45). These strategies allow adenovirus entry via the specific
ligand attached to the polylysine and should, in principle,
relieve the need for adenovirus-receptor levels on target cells.
The UV and psoralen-inactivation results further show that
the active principle in the endosomolysis is a portion of the
virus capsid. Agents specific for DNA disruption can inter-
fere with viral replication without seriously impairing the
DNA-delivery capacity of the virus, suggesting that the
protein component of the virus triggers the endosome dis-
ruption. This gives us hope that we can mimic the endoso-
molytic properties of the intact virus by using purified viral
components and completely dispense with the viral genome.
The delivery of large DNA molecules suggests many
applications of this technique. We must caution, however,
that the data in this paper demonstrate the successful delivery
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